- Home
- CUK vs INSM Comparison
CUK vs INSM Comparison
Compare CUK & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUK
- INSM
- Stock Information
- Founded
- CUK 1972
- INSM 1988
- Country
- CUK United States
- INSM United States
- Employees
- CUK N/A
- INSM N/A
- Industry
- CUK Marine Transportation
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- CUK Consumer Discretionary
- INSM Health Care
- Exchange
- CUK Nasdaq
- INSM Nasdaq
- Market Cap
- CUK 26.6B
- INSM 29.0B
- IPO Year
- CUK 2000
- INSM 2000
- Fundamental
- Price
- CUK $25.26
- INSM $165.29
- Analyst Decision
- CUK Strong Buy
- INSM Strong Buy
- Analyst Count
- CUK 18
- INSM 19
- Target Price
- CUK $33.22
- INSM $160.47
- AVG Volume (30 Days)
- CUK 1.7M
- INSM 1.8M
- Earning Date
- CUK 09-29-2025
- INSM 10-30-2025
- Dividend Yield
- CUK N/A
- INSM N/A
- EPS Growth
- CUK 61.65
- INSM N/A
- EPS
- CUK 1.94
- INSM N/A
- Revenue
- CUK $26,230,000,000.00
- INSM $398,105,000.00
- Revenue This Year
- CUK $9.15
- INSM $32.08
- Revenue Next Year
- CUK $3.92
- INSM $125.86
- P/E Ratio
- CUK $14.46
- INSM N/A
- Revenue Growth
- CUK 7.15
- INSM 21.15
- 52 Week Low
- CUK $13.65
- INSM $60.40
- 52 Week High
- CUK $29.80
- INSM $168.22
- Technical
- Relative Strength Index (RSI)
- CUK 37.57
- INSM 65.53
- Support Level
- CUK $26.37
- INSM $154.79
- Resistance Level
- CUK $27.18
- INSM $168.22
- Average True Range (ATR)
- CUK 0.77
- INSM 4.27
- MACD
- CUK 0.04
- INSM -1.02
- Stochastic Oscillator
- CUK 7.30
- INSM 78.21
About CUK Carnival Plc ADS ADS
Carnival is the largest global cruise company, with more than 90 ships in service at the end of fiscal 2024. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.